EP Wealth Advisors LLC Invests $110,000 in Emergent BioSolutions Inc. (NYSE:EBS)

EP Wealth Advisors LLC bought a new position in Emergent BioSolutions Inc. (NYSE:EBS) in the fourth quarter, HoldingsChannel.com reports. The fund bought 11,459 shares of the biopharmaceutical company’s stock, valued at approximately $110,000.

A number of other hedge funds have also modified their holdings of the stock. Invesco Ltd. grew its position in Emergent BioSolutions by 70.9% during the 4th quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock worth $14,722,000 after acquiring an additional 638,995 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Emergent BioSolutions by 67.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after acquiring an additional 444,790 shares during the last quarter. American Century Companies Inc. grew its position in Emergent BioSolutions by 23.4% during the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after acquiring an additional 404,667 shares during the last quarter. Trexquant Investment LP grew its position in Emergent BioSolutions by 59.3% during the 4th quarter. Trexquant Investment LP now owns 701,517 shares of the biopharmaceutical company’s stock worth $6,707,000 after acquiring an additional 261,099 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in Emergent BioSolutions during the 4th quarter worth approximately $1,831,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now directly owns 101,100 shares in the company, valued at $589,413. This trade represents a 25.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.20% of the company’s stock.

Emergent BioSolutions Stock Down 2.3%

Shares of EBS opened at $5.51 on Friday. The firm has a market capitalization of $299.40 million, a price-to-earnings ratio of -1.34 and a beta of 2.09. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The business’s fifty day moving average price is $5.13 and its two-hundred day moving average price is $7.82. Emergent BioSolutions Inc. has a 52 week low of $4.02 and a 52 week high of $15.10.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.22. The firm had revenue of $222.20 million for the quarter, compared to analyst estimates of $218.50 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. On average, analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions declared that its board has initiated a stock buyback program on Monday, March 31st that authorizes the company to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase up to 19% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on EBS shares. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a research report on Tuesday, April 1st. StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.